Program
zeprumetostat
Also written as “SHR2554”, “TLN-254” and “SHR2554 Tablets”.
Its studies are mostly in Lymphoma · Neoplasms · Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.
Drug pageZeprumetostat: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicineits history only | 166 open or running | phase 3since Nov 5, 2023 | Jul 10, 2018 | Apr 2027phase 2 · NCT06368167 |
| Treeline Biosciences | 11 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Treeline Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 11, 2024Named zeprumetostatINNProposed as its International Nonproprietary Name in WHO's List 131 · before, SHR2554, TLN-254
- Dec 10, 2024First study: phase 1 study in LymphomaFirst studyNCT06733441 · 50 enrolled · United States, Canada
Ahead
- Nov 15, 2026Primary completion: phase 1 study in LymphomaNCT06733441
TargetBeta
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule
Other programs on EZH2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mevrometostat | Pfizer | phase 3 | 7 |
| TR115rule | tarapeutics-science-inc | phase 3 | 3 |
| tulmimetostat | Novartis | phase 2 | 3 |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 2 |
| valemetostatrule | Daiichi Sankyo | phase 1 | 1 |
Studies
The one study Treeline Biosciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06733441Lymphoma · United States, Canada | 1 | Active, not recruiting | Nov 15, 2026 | 50 |
How it is read
Names in the registry
- “SHR2554”, 6 entries
- “TLN-254”, 2 entries
- “SHR2554 Tablets”, 2 entries
- “SHR2554 Tablet”, 1 entry
- “SHR2554; Chidamide analog tablets”, 1 entry
Codes read as this program: SHR2554.
Conditions, from the studies’ own filings
- Lymphoma, 3 studies
- Neoplasms, 3 studies
- Prostatic Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.